£4m dedicated to advancing the development and application of non-animal technologies, such as bioprinting human tissue
Owner/Developer: National Centre for the Replacement, Refinement & Reduction of Animals in Research (NC3Rs)
Fifteen business collaborations, carrying out early-stage investigations into the feasibility of novel non-animal technologies, have received support from five key funding bodies, including the NC3Rs.
The development of non-animal technologies is vital in the search for alternatives that can replace the use of animals in scientific research. Fifteen feasibility studies, carried out by collaborations between companies and academia, will look at a range of non-animal technologies. The technologies capitalise upon recent advances in the biosciences and engineering including; induced pluripotent stem cells, tissue engineering technologies, high-throughput platforms, computational modelling, novel imaging techniques and bioprinting technologies.
The NC3Rs, the UK’s innovation agency, the Technology Strategy Board, the Biotechnology and Biological Sciences Research Council, the Defence Science and Technology Laboratory and the Engineering and Physical Sciences Research Council have joined forces to fund the business-led projects which have the potential to change both the drug development and chemical testing landscape.
|Audience:||Scientists - Regulators - Industry - Researchers|
|User access:||Open access|
|Updating frequency:||08 July 2014|
|Relevance:||Replacement - Reduction|
|Purpose:||Documentation and information - Method development|
|Technology/Tools:||3D printing - Tissue engineering|
Did you find what you were looking for?Yes, I found it! No, I did not!
Thanks for your feedback! Please note that we cannot respond unless you supply your email address.
What are you looking for?
Please give us your feedback so we can improve the information on the page. Thank you in advance for your help. Please add your email address if you would like a reply.Please contact us by email if you have any questions.